Medtronic Endeavors To Gain Drug-Eluting Stent Share In Europe
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's ability to immediately launch 80,000Endeavor drug-eluting stents should help the firm to avoid the supply constraint issues faced by J&J
You may also be interested in...
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study
Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S